REGN13335 Clinical Trials (2026): 2 Studies for Healthy Volunteers & Pulmonary Arterial Hypertension (PAH)
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 REGN13335 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Healthy Volunteers & Pulmonary Arterial Hypertension (PAH)) and 155 total planned enrollment. 1 REGN13335 clinical trial is actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT07318597 (Sep 2028).
Where to Participate: All REGN13335 Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting REGN13335trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CO | University of Colorado Denver | Aurora80045 | NCT07318597 | Map |
REGN13335 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | Total |
|---|---|---|---|
| P1 | 1 | 1 | |
| P2 | 1 | 1 |
Recruiting REGN13335 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07318597 | ILLUMINATEStudy of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) | P2 | Pulmonary Arterial Hypertension (PAH) | 99 | May 2026 |
REGN13335 clinical trials by indication
Pulmonary Arterial Hypertension (PAH) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07318597 | ILLUMINATE | P2 | recruiting | Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) |
Healthy Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06137482 | IV | P1 | completed | A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants |
REGN13335 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ILLUMINATE | NCT07318597 | P2 | recruiting | Pulmonary Arterial Hypertension (PAH) | 99 | — |
All REGN13335 trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07318597 | ILLUMINATE | Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) | P2 | recruiting | 99 | Regeneron Pharmaceuticals | May 2026 |
| NCT06137482 | IV | A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants | P1 | completed | 56 | Regeneron Pharmaceuticals | Dec 2023 |
REGN13335 clinical trials: frequently asked questions
- How many REGN13335 clinical trials are there?
- 2 REGN13335 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 1 is marked completed.
- Are REGN13335 clinical trials recruiting in 2026?
- Yes — 1 REGN13335 trial is actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is REGN13335 being studied for?
- REGN13335 is being studied for Healthy Volunteers, Pulmonary Arterial Hypertension (PAH). The trials are grouped by indication on this page.
- What phase is REGN13335 in?
- REGN13335 clinical trials span 1 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors REGN13335 clinical trials?
- The lead sponsor across the most REGN13335 trials is Regeneron Pharmaceuticals. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming REGN13335as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: